At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
Talazoparib +2 moredrug
Likely dose
Talazoparib 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1 OPEN-LABEL, TWO-ARM,DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND RIFAMPIN ON THE PHARMACOKINETICS OF TALAZOPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS
In Brief
A Phase 1 clinical trial evaluating Talazoparib, Itraconazole, and 1 other intervention for Advanced Solid Tumors. Completed, enrolled 36 participants across 7 sites in 4 countries.
Detailed Summary
This is a study in patients with advanced solid tumors for the investigation of P-gp inhibition and induction on the PK of talazoparib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesHungary, Moldova, Poland, Russia
CollaboratorsMedivation, Inc.
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedMar 2017
Primary CompletionDec 2017
Study CompletionJan 2018
TodayJul 2026
First PostedMar 13, 2017
Enrollment StartNov 7, 2016
Primary CompletionDec 19, 2017
Study CompletionJan 20, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.3 years ago
Interventions
Talazoparibdrug
Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
Itraconazoledrug
100 mg oral dose
Rifampindrug
600 mg oral dose